Cascadian Therapeutics Inc. (NASDAQ:CASC) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Tuesday.

According to Zacks, “Cascadian Therapeutics, Inc. is a biopharmaceutical company specializing in developing innovative therapeutic product candidates for the treatment of cancer. The company’s product candidate is ONT-380, an orally active and selective small molecule HER2 inhibitor which is in preclinical trial stage. Cascadian Therapeutics, Inc., formerly known as Oncothyreon Inc., is headquartered in Seattle, Washington. “

Separately, Cowen and Company reiterated a “buy” rating on shares of Cascadian Therapeutics in a research report on Monday, October 10th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $3.20.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

Cascadian Therapeutics (NASDAQ:CASC) traded up 0.77% on Tuesday, reaching $1.31. The company had a trading volume of 307,407 shares. The company’s 50-day moving average price is $1.35 and its 200 day moving average price is $1.18. The firm’s market capitalization is $177.26 million. Cascadian Therapeutics has a 1-year low of $0.82 and a 1-year high of $3.75.

Cascadian Therapeutics (NASDAQ:CASC) last issued its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by $0.14. During the same period last year, the business posted ($0.11) EPS. On average, equities analysts forecast that Cascadian Therapeutics will post $5.02 EPS for the current year.

In related news, insider Scott Dunseth Myers purchased 45,000 shares of Cascadian Therapeutics stock in a transaction that occurred on Wednesday, August 17th. The stock was purchased at an average price of $1.15 per share, for a total transaction of $51,750.00. Following the transaction, the insider now directly owns 107,500 shares in the company, valued at $123,625. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 19.40% of the company’s stock.

About Cascadian Therapeutics

Cascadian Therapeutics, Inc, formerly Oncothyreon Inc, is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor.

5 Day Chart for NASDAQ:CASC

Get a free copy of the Zacks research report on Cascadian Therapeutics (CASC)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Cascadian Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cascadian Therapeutics Inc. and related companies with's FREE daily email newsletter.